• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background

    Antibody Drug Conjugate Companies

    ID: MRFR/HC/0607-HCR
    200 Pages
    Rahul Gotadki
    October 2025

    Antibody Drug Conjugate companies focus on the development of innovative cancer treatments. They specialize in combining monoclonal antibodies with potent drugs, creating targeted therapies that deliver medication directly to cancer cells. These companies contribute to advancing precision medicine in oncology.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Antibody Drug Conjugate Market Research Report – Forecast to 2035 Infographic
    Summary Table of Contents Segmentation Download PDF

    Top Industry Leaders in the Antibody Drug Conjugate Market

    Antibody Drug Conjugate Key Companies

     

    Latest Antibody Drug Conjugate Companies Update


    Pfizer's $43 Billion Seagen Acquisition This mega-deal closed in March 2023, solidifying Pfizer's position as a leading ADC player. It signifies the immense potential and projected value of the market.


    Merck & Daiichi Sankyo Join Forces A $22 billion collaboration inked in December 2023 will see the development and commercialization of three promising ADC candidates. This partnership highlights the importance of strategic alliances in advancing ADC research.


    Next-Gen Linkers for Enhanced Targeting Companies like ImmunoGen are developing novel linker technologies to improve ADC stability and delivery to targeted cancer cells.


    List of Antibody Drug Conjugate Key Companies in the Market



    • ADC Therapeutics

    • Takeda Pharmaceutical Company Ltd.

    • GlaxoSmithKline Plc

    • Hoffmann-La Roche Ltd.

    • Daiichi Sankyo Company Ltd.

    • Pfizer Inc.

    • Seagen Inc.

    • Gilead Sciences Inc.

    • Astellas Pharma